• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Definium Therapeutics Inc.

    3/25/26 5:39:38 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $DFTX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001331843
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    DEFINIUM THERAPEUTICS, INC.
    SEC File Number
    001-40360
    Address of Issuer
    ONE WORLD TRADE CENTER
    SUITE 8500
    NEW YORK
    NEW YORK
    10007
    Phone
    212-220-6633
    Name of Person for Whose Account the Securities are To Be Sold
    MARK SULLIVAN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    10702197665.949969812903/25/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/25/2026Restricted stock vesting under a registered planIssuerCheckbox not checked1070203/25/2026Services Rendered

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Mark Sullivan
    ONE WORLD TRADE CENTER
    SUITE 8500
    NEW YORK � NY � 10007
    Common12/26/202511276148244.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/25/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Mark Sullivan

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $DFTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DFTX

    DatePrice TargetRatingAnalyst
    2/24/2026$25.00Outperform
    Wolfe Research
    1/30/2026$30.00Buy
    Jefferies
    More analyst ratings

    $DFTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Definium Therapeutics with a new price target

    Wolfe Research initiated coverage of Definium Therapeutics with a rating of Outperform and set a new price target of $25.00

    2/24/26 7:52:18 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies initiated coverage on Definium Therapeutics with a new price target

    Jefferies initiated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $30.00

    1/30/26 6:43:41 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    SEC Filings

    View All

    SEC Form 144 filed by Definium Therapeutics Inc.

    144 - Definium Therapeutics, Inc. (0001813814) (Subject)

    3/25/26 5:39:38 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Definium Therapeutics Inc.

    10-K - Definium Therapeutics, Inc. (0001813814) (Filer)

    2/26/26 4:16:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Definium Therapeutics, Inc. (0001813814) (Filer)

    2/26/26 4:10:27 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Karlin Daniel

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    3/26/26 6:43:44 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Sullivan Mark

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    3/26/26 6:42:48 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Barrow Robert

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    3/26/26 6:42:23 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States

    The annual prevalence of newly diagnosed generalized anxiety disorder (GAD) increased from 5.4% in 2020 to 6.6% in 2023 The 3-year total prevalence of GAD reached 10.3%, representing more than 1 in 10 U.S. adults Definium Therapeutics, Inc. ("Definium" or the "Company"), announced results from a retrospective, longitudinal study published in the Journal of Mood and Anxiety Disorders examining the real-world prevalence, incidence, and burden of GAD in the United States healthcare system from 2020 to 2023. These findings show a steadily increasing diagnosed prevalence of GAD and highlight a substantial and growing burden affecting more than 1 in 10 adults in the U.S. Together, these resul

    3/31/26 7:00:00 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Definium Therapeutics Announces New Employee Inducement Grants

    Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 55,580 common shares of the Company (the "Options") with effective grant dates of March 16, 2026 and March 30, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversar

    3/30/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026

    Definium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced additional details for its Investor & Analyst Day in New York on April 22, 2026. Presentations and live question and answer sessions will be led by members of Definium's executive leadership team and external key opinion leaders who will provide clinical and real-world context on the evolving treatment landscape in generalized anxiety disorder (GAD) and major depressive disorder (MDD). Key areas of discussion will include DT120 ODT (lysergide tartrate), Defin

    3/26/26 7:00:00 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Financials

    Live finance-specific insights

    View All

    Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

    Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026 Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026 $411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028 Conference call scheduled today at 4:30 p.m. EST Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorder

    2/26/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Leadership Updates

    Live Leadership Updates

    View All

    Definium Therapeutics Appoints Roger Adsett to Board of Directors

    Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium's next phase of growth Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. "We are thrilled to welcome Roger to our Board of Directors," said Rob Barrow, Chief Executive Officer of Definium Therapeutics. "Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful market impact. At Insmed, he's led the development of world-class commercial and operation

    1/29/26 7:00:00 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care